The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years

Journal of Medical Microbiology

Volumn 63, Issue PART 6, 2014, Pages 819-823

  Lee, Jong Han ^a   Lee, Yangsoon ^b   Lee, Kyungwon ^b   Riley, Thomas V ^c   Kim, Heejung ^b  

^a Korea University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTETAN; CIPROFLOXACIN; CLINDAMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ERYTHROMYCIN; IMIPENEM; MOXIFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; DNA SEQUENCE; GENETIC CODE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIBOTYPING; SEROPREVALENCE; TERTIARY CARE CENTER;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; RIBOTYPING; TERTIARY CARE CENTERS; TIME FACTORS;

EID: 84901365137     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.072082-0     Document Type: Article

References (26)

1. Ackermann, G., Tang, Y. J., Kueper, R., Heisig, P., Rodloff, A. C., Silva, J., Jr & Cohen, S. H. (2001). Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 45, 2348-2353.
2. Ackermann, G., Degner, A., Cohen, S. H., Silva, J., Jr & Rodloff, A. C. (2003). Prevalence and association of macrolide-lincosamidestreptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 51, 599-603.
3. Barbut, F., Decré, D., Lalande, V., Burghoffer, B., Noussair, L., Gigandon, A., Espinasse, F., Raskine, L., Robert, J. & other authors (2005). Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 54, 181-185.
4. Barbut, F., Mastrantonio, P., Delmée, M., Brazier, J., Kuijper, E., Poxton, I. & European Study Group on Clostridium difficile (ESGCD) (2007). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13, 1048-1057.
5. Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., Kuijper, E. J. & ECDIS Study Group (2011). Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377, 63-73.
6. Bourgault, A. M., Lamothe, F., Loo, V. G., Poirier, L. & CDAD-CSI Study Group (2006). In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob Agents Chemother 50, 3473-3475.
7. Cheknis, A. K., Zukowski, W. E., Petrella, A. K., Nagaro, J., Sambol, S. P., Figueroa, I., Li, L. Q., Perdue, E., Gelone, S. P. & other authors (2009). Prevalence of REA types of Clostridium difficile from U.S. hospitals (2006-2009). In Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract K-2075. San Francisco, CA.
8. CLSI (2012). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard M11-A8. Wayne, PA: Clinical and Laboratory Standards Institute.
9. CLSI (2013). Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute.
10. Dridi, L., Tankovic, J., Burghoffer, B., Barbut, F. & Petit, J. C. (2002). gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46, 3418-3421.
11. Drudy, D., Quinn, T., O'Mahony, R., Kyne, L., O'Gaora, P. & Fanning, S. (2006). High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-Bpositive Clostridium difficile. J Antimicrob Chemother 58, 1264-1267.
12. Heddle, J. & Maxwell, A. (2002). Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob Agents Chemother 46, 1805-1815.
13. Huang, H., Fang, H., Weintraub, A. & Nord, C. E. (2009a). Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 15, 1170- 1173.
14. Huang, H., Weintraub, A., Fang, H. & Nord, C. E. (2009b). Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 34, 516-522.
15. Huang, H., Wu, S., Wang, M., Zhang, Y., Fang, H., Palmgren, A. C., Weintraub, A. & Nord, C. E. (2009c). Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents 33, 339-342.
16. Kato, H., Kato, N., Watanabe, K., Iwai, N., Nakamura, H., Yamamoto, T., Suzuki, K., Kim, S. M., Chong, Y. & Wasito, E. B. (1998). Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 36, 2178-2182.
17. Kim, H., Jeong, S. H., Roh, K. H., Hong, S. G., Kim, J. W., Shin, M. G., Kim, M. N., Shin, H. B., Uh, Y. & other authors (2010). Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 30, 491-497.
18. Lyerly, D. M., Krivan, H. C. & Wilkins, T. D. (1988). Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1, 1-18.
19. McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Jr, Kazakova, S. V., Sambol, S. P., Johnson, S. & Gerding, D. N. (2005). An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353, 2433-2441.
20. O'Donoghue, C. & Kyne, L. (2011). Update on Clostridium difficile infection. Curr Opin Gastroenterol 27, 38-47.
21. Sawabe, E., Kato, H., Osawa, K., Chida, T., Tojo, N., Arakawa, Y. & Okamura, N. (2007). Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur J Clin Microbiol Infect Dis 26, 695- 703.
22. Spigaglia, P., Barbanti, F., Mastrantonio, P., Brazier, J. S., Barbut, F., Delmée, M., Kuijper, E., Poxton, I. R. & European Study Group on Clostridium difficile (ESGCD) (2008). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57, 784-789.
23. Spigaglia, P., Barbanti, F., Dionisi, A. M. & Mastrantonio, P. (2010). Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol 48, 2892-2896.
24. Stubbs, S. L., Brazier, J. S., O'Neill, G. L. & Duerden, B. I. (1999). PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37, 461-463.
25. Stubbs, S., Rupnik, M., Gibert, M., Brazier, J., Duerden, B. & Popoff, M. (2000). Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 186, 307- 312.
26. Tae, C. H., Jung, S. A., Song, H. J., Kim, S. E., Choi, H. J., Lee, M., Hwang, Y., Kim, H. & Lee, K. (2009). The first case of antibioticassociated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci 24, 520-524.